000			05500cam a2200421Ii 4500
001			96328
003			ES-MaUEC
005			20230102112749.0
006			m o d
007			cr cnu|||unuuu
008			170713t20172017ja a ob 000 0 eng d
020			_a4431564357 _q(electronic bk.)
020			_a9784431564355 _q(electronic bk.)
020			_z9784431564331
040			_aN$T _cN$T _dEBLCP _dN$T _dGW5XE _dYDX _dOCLCF _dKOS _dOCLCO _dUAB _dOCLCO _dESU _dIOG _dCOO _dNJR _dUPM _dMERER _dVT2 _dES-MaUEC _bspa
050		4	_aRC280.L9 _b2017 EB
245	0	0	_aRadiation therapy for extranodal lymphomas _cKeisuke Sasai, Masahiko Oguchi, editors.
264		1	_aTokyo, Japan _bSpringer International Publishing Nature _c2017
264		4	_c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
504			_aIncluye referencias bibliográficas
505	0		_aPreface; Contents; 1: Primary Central Nervous System Lymphomas; 1.1 Introduction; 1.2 Pathology; 1.3 Pretreatment Evaluation; 1.4 Treatment Strategy; 1.5 Chemotherapy; 1.6 Radiation Therapy (Indications); 1.6.1 Consolidation RT in Patients with CR After Chemotherapy; 1.6.2 RT for Refractory or Recurrent PCNSL After Chemotherapy Alone; 1.6.3 RT for Progressive Disease During Initial Chemotherapy; 1.6.4 Re-irradiation for Recurrence After Whole-Brain Radiotherapy; 1.6.5 Palliative RT; 1.6.6 RT in Elderly Patients; 1.6.7 Radiotherapy for Intraocular Involvement by PCNSL
505	8		_a1.6.8 RT for Primary Intraocular Lymphoma1.7 Radiation Therapy (Treatment Procedures); 1.7.1 RT Planning; 1.7.2 Whole-Brain Radiotherapy (Fig. 1.2); 1.7.2.1 Target Volumes; 1.7.2.2 Radiation Field; 1.7.2.3 Beam Energy; 1.7.2.4 Dose and Fractionation; 1.7.3 Partial Brain RT (Fig. 1.3); 1.7.3.1 Target Volumes; 1.7.3.2 RT Technique; 1.7.3.3 Dose; 1.8 Outcomes; 1.8.1 Survival; 1.8.2 Prognostic Factors; 1.9 Toxicity; 1.9.1 Acute Toxicity; 1.9.2 Late Toxicity; References; 2: Ocular Adnexal Lymphoma; 2.1 Introduction; 2.2 Pathology, Immunophenotype, and Cytogenetic Abnormalities
505	8		_a2.2.1 MALT Lymphoma2.3 Clinical Features; 2.3.1 MALT Lymphoma; 2.3.2 DLBCL; 2.4 Pretreatment Evaluation and Staging; 2.5 Prognostic Factors; 2.6 Treatment Strategy; 2.6.1 MALT Lymphoma; 2.6.2 Diffuse Large B-Cell Lymphoma; 2.7 Radiation Therapy; 2.7.1 Clinical Target Volume; 2.7.1.1 MALT Lymphoma and Other Indolent Lymphomas; 2.7.1.2 DLBCL and Other Aggressive Lymphomas; 2.7.2 Dose; 2.7.2.1 MALT Lymphoma and Other Indolent Lymphomas; 2.7.2.2 DLBCL; 2.7.3 Radiation Therapy Techniques; 2.8 Outcomes; 2.8.1 MALT Lymphoma; 2.8.1.1 Response
505	8		_a2.8.1.2 Survival and Disease Progression2.8.2 Diffuse Large B-Cell Lymphoma; 2.9 Toxicity; 2.10 Summary; References; 3: Extranodal NK/T Cell Lymphoma, Nasal Type; 3.1 Introduction; 3.2 Pathology; 3.3 Pretreatment Evaluation and Prognostic factors; 3.4 Treatment Strategy; 3.5 Chemotherapy; 3.6 Radiation Therapy (Indications); 3.7 Radiation Therapy (Treatment Procedures); 3.7.1 RT Planning; 3.7.2 Extended Involved Site Radiation Therapy and Target volumes; 3.7.3 Radiation Delivery; 3.7.4 Dose and Fractionation; 3.8 Outcomes; 3.8.1 Survival; 3.8.2 Failure Patterns
505	8		_a3.9 Toxicity3.9.1 Acute Toxicity; 3.9.2 Late Toxicity; References; 4: Thyroid Lymphoma; 4.1 Introduction; 4.2 Pathology; 4.3 Lymphoma Subtype for Radiation Therapy; 4.4 Pretreatment Evaluation and Staging; 4.5 Prognostic Factors; 4.6 Treatment Strategy; 4.6.1 DLBCL; 4.6.2 MALT; 4.7 Radiation Therapy; 4.7.1 Planning CT; 4.7.2 Gross Tumor Volume (GTV); 4.7.3 Clinical Target Volume (CTV) and Planning Target Volume (PTV); 4.7.4 Dose; 4.7.5 Radiation Therapy Techniques; 4.8 Outcomes; 4.9 Toxicity; References; 5: Pyothorax-Associated Lymphoma; 5.1 Etiology and Pathology
520	3		_aThis book is devoted to sharing the knowledge and experience of expert radiation therapy (RT) for extranodal lymphomas. For that purpose, the authors provide clinical-pathological information, precise RT techniques, and treatment results, i.e., disease control and survival, of all extranodal lymphomas. Over the past 10 years, specific techniques have been updated, from 3-dimensional conformal RT to intensity modulated RT / volumetric-modulated arc therapy. Precise targeting such as image-guided RT and active breathing control are now capable of treating lymphoma lesions that shift with respiration or peristalsis. This book, serving as a guide, provides the necessary knowledge for radiation oncology, practice, and planning involving the RT techniques of treating extranodal lymphomas. In addition, it equips oncologists, hematologists, and medical oncologists to refer patients with extranodal lymphomas to radiation oncologists for appropriate treatment in a timely manner. Therefore this volume will greatly benefit all oncologists, including radiation and medical oncologists, as well as hematologists.
650		7	_aLinfomas _xTreatment. _2embne _0(OCoLC)fst01004329 _0 _9668066
700	1		_aOguchi, Masahiko, _eeditor literario
700	1		_aSasai, Keisuke, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-4-431-56435-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c96328 _d96328 _x1